-
Listing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLes merSeamless listing, trading, clearing and settlement for fixed income
-
Trading
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLes mer
Seamless listing, trading, clearing and settlement for fixed income
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLes mer
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLes merEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Les merThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperNext generation of indicesLes merThis white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Les merShaping capital markets for future generations
Arseus celebrates new name Fagron
By sounding the gong Ger van Jeveren, CEO of Fagron, celebrates the name change of Arseus into Fagron. The new trading symbol of Fagron is: FAGR.
Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimizing and innovating pharmaceutical compounding worldwide. Fagron supplies pharmaceutical raw materials, equipment & supplies, concepts and pharmaceutical compounding to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron’s own R&D organization consists of 200 pharmacists who are working continually on developing new formulations for specific patients and patient groups.
For more information: www.fagron.com